{'fraction_non_alphanumeric': 0.02403846153846154, 'fraction_numerical': 0.003605769230769231, 'mean_word_length': 5.5078125, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Editorial: the role for PIVKA‐II measurement after HCV elimination by direct‐acting antivirals in terms of prediction of hepatocellular carcinoma—authors' reply

We read with interest the editorial from Dr Ogawa and thank him for his comments about our research.1,2 Concerning the possibility that patients with high PIVKAII levels at baseline could harbour hepatocellular carcinoma (HCC) nodules at the time of directacting antivirals (DAA) initiation, in our cohort last HCC surveillance imaging was performed within 3 months before the start of the treatment. As our study was retrospective and conducted in a clinical practice setting, we could not perform a secondlevel imaging technique such as enhanced dynamic computed tomography (CT) or magnetic resonance imaging (MRI). We agree that a CT/MRI could be useful to definitely